<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576276</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000358</org_study_id>
    <nct_id>NCT01576276</nct_id>
  </id_info>
  <brief_title>A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects</brief_title>
  <official_title>A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy right-handed volunteers aged 21 to 50 needed for a research study of the effects of
      morphine and ketorolac on brain activity in response to pain stimuli as measured by
      functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET). Study
      will be conducted on six separate days not requiring an overnight stay in the hospital.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI Signal Changes</measure>
    <time_frame>one day</time_frame>
    <description>Obtain information about brain activity, including BOLD (Blood-oxygen-level dependent) signal, using an fMRI system. Data analysis was applied using SPM 12 with a standard pipeline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Ratings</measure>
    <time_frame>One day</time_frame>
    <description>The primary endpoint was the morphine and ketorolac conditioning effects as indicated by subjective pain rating changes between pain only (a control condition with no injection of glucose, but subject's did see an image of an hour class displaying how much time they had before receiving a painful stimuli ) and pain+glucose (subjects received a glucose injection accompanied by an injection schematic followed by a painful stimuli) within the morphine and ketorolac groups. We used the Gracely pain rating scale (ranging from 0, no sensation to 20, extremely painful.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>Morphine condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Integrated MR-PET scan</intervention_name>
    <description>Integrated MR-PET scan using [11C]diprenorphine</description>
    <arm_group_label>Morphine condition</arm_group_label>
    <arm_group_label>Ketorolac condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>3 administrations of ketorolac over course of study</description>
    <arm_group_label>Ketorolac condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female adults, aged 21-50

          2. No contraindications to fMRI scanning

          3. Within 15% of normal BMI

          4. Right handed (dominant hand is right hand)

          5. Have taken an opioid drug at least once in the past (for example, after a surgery)

        Exclusion Criteria:

          1. Current or past history of major medical, neurological, or psychiatric illness

          2. Women who are pregnant or breast feeding, have gone through menopause, or have
             irregular menstrual cycles (length of cycle must be within 26 to 32 days)

          3. Contraindications to morphine administration:

               -  i) Hypersensitivity to morphine or other phenanthrene-derivative opioid agonists
                  (codeine, oxycodone, etc.), morphine salts, or any component of the product

               -  ii) Concomitant use of other CNS depressants including antihistamines or alcohol

               -  iii) History of drug or alcohol abuse

               -  iv) History of head trauma

               -  v) History of liver problems

               -  vi) Pre-existing respiratory conditions (ex. COPD, asthma)

               -  vii) Current use of any drugs that interact with morphine

          4. Contraindications to ketorolac administration

               -  i) Allergic-type reaction, or urticaria in response to exposure to aspirin or
                  other NSAIDS

               -  ii) Concomitant aspirin or NSAID use

               -  iii) Hypersensitivity previously demonstrated to ketorolac tromethamine or to any
                  product component

               -  iv) Peptic ulcer disease (active or history), or other gastrointestinal problems

               -  vi) Current use of any drugs that interact with ketorolac (ex. heparin/warfarin)

               -  vii) History of bleeding disorder

               -  viii) Low body weight, under 50 kg

          5. Contraindications to fMRI scanning (including cardiac pacemaker, metal implants,
             claustrophobia, pregnancy)

          6. Contraindications to either of the emergency medications (Ondansetron or Narcan)

          7. History of head trauma

          8. High blood pressure (&gt;140 systolic, &gt;90 diastolic)

          9. History of impaired urinary elimination

         10. Major kidney problems, bleeding problems, severe dehydration, or recovering from a
             recent surgery (within past year).

         11. Instability of responses to experimental pain (see Study Procedures Section)

         12. History of asthma

         13. History of diabetes

         14. Liver Function Test results greater than 2.5 times the upper limit of normal (ULN) at
             Screening

         15. History of smoking (past or current)

         16. Use of psychotropic drugs, hormone treatments (including hormonal birth control)
             within 1 year

         17. Non-fluent speaker of English

         18. Positive urine drug screen (i.e. positive on any of the 10 measures tested, including
             cocaine, marijuana, opiates, amphetamines, methamphetamines, phencyclidine,
             barbiturates, benzodiazepines, methadone, and tricyclic antidepressants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <results_first_submitted>February 8, 2018</results_first_submitted>
  <results_first_submitted_qc>April 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2018</results_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jian Kong</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Analgesics, Non-Narcotic</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Morphine Condition</title>
          <description>Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine
Morphine: 3 administrations of morphine over course of study</description>
        </group>
        <group group_id="P2">
          <title>Ketorolac Condition</title>
          <description>Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine
Ketorolac: 3 administrations of ketorolac over course of study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Morphine Condition</title>
          <description>Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine
Morphine: 3 administrations of morphine over course of study</description>
        </group>
        <group group_id="B2">
          <title>Ketorolac Condition</title>
          <description>Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine
Ketorolac: 3 administrations of ketorolac over course of study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="3.3"/>
                    <measurement group_id="B2" value="26.0" spread="4.9"/>
                    <measurement group_id="B3" value="25.5" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Ratings</title>
          <population>Some subjects were dropped before or during the MRI scan in which baseline pain ratings were collected. We used the Gracely Sensory Pain Scale (0-20; 0: no pain, 20: intolerable pain) to rate the pain subject's experienced.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="2.6"/>
                    <measurement group_id="B2" value="11.6" spread="2.2"/>
                    <measurement group_id="B3" value="11.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>fMRI Signal Changes</title>
        <description>Obtain information about brain activity, including BOLD (Blood-oxygen-level dependent) signal, using an fMRI system. Data analysis was applied using SPM 12 with a standard pipeline.</description>
        <time_frame>one day</time_frame>
        <population>Here we present the average fMRI (functional MRI) signal changes of clusters that survived a threshold of 0.005 with10 continuous voxels. We only reported beta values in pain related areas.</population>
        <group_list>
          <group group_id="O1">
            <title>fMRI Signal Change</title>
            <description>We used SPM 12 to analyze the data, and compared the fMRI signal change during pressure pain between 1. morphine injection cue vs. control cue, 2. ketorolac injection cue vs. control cue. A threshold of p &lt; 0.005 with 10 continuous voxels was applied.</description>
          </group>
        </group_list>
        <measure>
          <title>fMRI Signal Changes</title>
          <description>Obtain information about brain activity, including BOLD (Blood-oxygen-level dependent) signal, using an fMRI system. Data analysis was applied using SPM 12 with a standard pipeline.</description>
          <population>Here we present the average fMRI (functional MRI) signal changes of clusters that survived a threshold of 0.005 with10 continuous voxels. We only reported beta values in pain related areas.</population>
          <units>Beta value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>morphine injection cue at operculum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>morphine control cue at operculum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ketorolac injection cue at operculum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ketorolac control cue at operculum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ketorolac injection cue at insula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ketorolac control cue at insula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Ratings</title>
        <description>The primary endpoint was the morphine and ketorolac conditioning effects as indicated by subjective pain rating changes between pain only (a control condition with no injection of glucose, but subject's did see an image of an hour class displaying how much time they had before receiving a painful stimuli ) and pain+glucose (subjects received a glucose injection accompanied by an injection schematic followed by a painful stimuli) within the morphine and ketorolac groups. We used the Gracely pain rating scale (ranging from 0, no sensation to 20, extremely painful.</description>
        <time_frame>One day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Morphine Condition</title>
            <description>Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine
Morphine: 3 administrations of morphine over course of study</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac Condition</title>
            <description>Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine
Ketorolac: 3 administrations of ketorolac over course of study</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Ratings</title>
          <description>The primary endpoint was the morphine and ketorolac conditioning effects as indicated by subjective pain rating changes between pain only (a control condition with no injection of glucose, but subject's did see an image of an hour class displaying how much time they had before receiving a painful stimuli ) and pain+glucose (subjects received a glucose injection accompanied by an injection schematic followed by a painful stimuli) within the morphine and ketorolac groups. We used the Gracely pain rating scale (ranging from 0, no sensation to 20, extremely painful.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="1.45"/>
                    <measurement group_id="O2" value="-0.97" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for each participant over a 3 hours period (from time of drug administration until they left 3 hours later). We collected this for every participant throughout our study.</time_frame>
      <desc>Our definitions are consistent. After every drug administration we asked a standard questionnaire, which we also asked again a couple of hours following the initial drug administration. Specifically, we asked subjects if they felt nauseous, indigestion, itching, spacey/drugged, lightheadedness/faint, sense of difficulty concentrating, or sleepy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Morphine Condition</title>
          <description>Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine
Morphine: 3 administrations of morphine over course of study</description>
        </group>
        <group group_id="E2">
          <title>Ketorolac Condition</title>
          <description>Integrated MR-PET scan: Integrated MR-PET scan using [11C]diprenorphine
Ketorolac: 3 administrations of ketorolac over course of study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Drug related reactions</sub_title>
                <description>Drug related reactions to morphine and ketorolac, including feeling nauseous, spacey, and drugged.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jian Kong</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-7893</phone>
      <email>jkong2@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

